OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION
Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the application and is allowed for treatment of un...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2007-12-01
|
| Series: | Педиатрическая фармакология |
| Online Access: | https://www.pedpharma.ru/jour/article/view/689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839587244235554816 |
|---|---|
| author | T.V. Kulichenko |
| author_facet | T.V. Kulichenko |
| author_sort | T.V. Kulichenko |
| collection | DOAJ |
| description | Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the application and is allowed for treatment of uncontrolled bronchial asthma among adults and children aged 12 and over in different countries of the world, including Russia. High omalizumab assisted treatment costs, as well as the need in the monthly visits to the doctor for the omalizumab injections are justified for the patients, requiring repeat hospitalizations, emergency medical aid, using high doses of the inhalation and/or systemic glucocorticosteroids. The article reviews the criteria for the selection of patients fit for omalizumab assisted treatment.Key words: omalizumab, anti-ige-antibodies, bronchial asthma, allergic rhinitis, treatment, children. |
| format | Article |
| id | doaj-art-f2f672354fcf4fa9b7c17a5d73f0c91a |
| institution | Matheson Library |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2007-12-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-f2f672354fcf4fa9b7c17a5d73f0c91a2025-08-03T19:21:20ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892007-12-01465155685OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATIONT.V. Kulichenko0Scientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowAntibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the application and is allowed for treatment of uncontrolled bronchial asthma among adults and children aged 12 and over in different countries of the world, including Russia. High omalizumab assisted treatment costs, as well as the need in the monthly visits to the doctor for the omalizumab injections are justified for the patients, requiring repeat hospitalizations, emergency medical aid, using high doses of the inhalation and/or systemic glucocorticosteroids. The article reviews the criteria for the selection of patients fit for omalizumab assisted treatment.Key words: omalizumab, anti-ige-antibodies, bronchial asthma, allergic rhinitis, treatment, children.https://www.pedpharma.ru/jour/article/view/689 |
| spellingShingle | T.V. Kulichenko OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION Педиатрическая фармакология |
| title | OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION |
| title_full | OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION |
| title_fullStr | OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION |
| title_full_unstemmed | OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION |
| title_short | OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION |
| title_sort | omalizumab for children with bronchial asthma indications to application |
| url | https://www.pedpharma.ru/jour/article/view/689 |
| work_keys_str_mv | AT tvkulichenko omalizumabforchildrenwithbronchialasthmaindicationstoapplication |